Cerebrotendinous Xanthomatosis patients with late diagnosed in single orthopedic clinic: two novel variants in the CYP27A1 gene
Open Access
- 9 February 2024
- journal article
- research article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 19 (1) , 1-13
Abstract
Background: Cerebrotendinous Xanthomatosis (CTX) is a rare autosomal recessive lipid storage disorder caused by loss of function variants in the CYP27A1 gene which encodes sterol 27-hydroxylase, on chromosome 2q35. Although the symptoms begin commonly in infancy, CTX diagnosis is often delayed. The aim of this study is to review the orthopedic findings of the disease by providing an overview of the clinical features of the disease. It is to raise awareness of this condition for which early diagnosis and treatment are important. Methods: We retrospectively evaluated the clinical, laboratory, radiological, and genetic findings of eight patients from four families who were admitted to our Orthopedics and Traumatology Department between 2017 and 2022 due to bilateral Achilles tendon xanthomas, were found to have high cholestanol and CYP27A1 gene mutations. Results: The mean age of patients was 37, and five of them were male. The mean age at the onset of symptoms was 9.25 years. The mean age of initial diagnosis was 33.75 years. Between symptom onset and clinical diagnosis, an average delay of 24.5 years was observed. All patients had bilateral Achilles tendon xanthoma. Notably, a novel variant (c.670_671delAA) in CYP27A1 gene was identified in three patients who also presented with peripheral neuropathy and bilateral pes cavus. One patient had osteoporosis and four patients had osteopenia. Five patients had a history of bilateral cataracts. Furthermore, three of the patients had early-onset chronic diarrhea and three of the patients had ataxia. Two of the patients had epilepsy and seven of the patients had behavior-personality disorder. All patients had low intelligence, but none of them had cardiac disease. Conclusion: We present the diagnostic process and clinical features which the largest CTX case series ever reported from single orthopedic clinic. We suggest that patients with normal cholesterol levels presenting with xanthoma being genetically analyzed by testing at their serum cholestanol level, and that all siblings of patients diagnosed with CTX be examined.Keywords
This publication has 52 references indexed in Scilit:
- A compound heterozygous mutation of CYP27A1 gene in a Taiwanese patient with cerebrotendinous xanthomatosisJournal of Orthopaedic Science, 2011
- 2 Novel deletions of the sterol 27-hydroxylase gene in a Chinese Family with Cerebrotendinous XanthomatosisBMC Neurology, 2011
- A novel mutation in the sterol 27-hydroxylase gene of a woman with autosomal recessive cerebrotendinous xanthomatosisOrphanet Journal of Rare Diseases, 2010
- Cerebrotendinous xanthomatosis: An inborn error in bile acid synthesis with defined mutations but still a challengeBiochemical and Biophysical Research Communications, 2010
- Vitamin D DeficiencyNew England Journal of Medicine, 2007
- Cerebrotendinous XanthomatosisJournal of Child Neurology, 2003
- Human Gene Mutation Database (HGMD®): 2003 updateHuman Mutation, 2003
- Cerebrotendinous xanthomatosisNeuromuscular Disorders, 2000
- Exon skipping in the sterol 27-hydroxylase gene leads to cerebrotendinous xanthomatosisHuman Genetics, 1997
- Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO reportOsteoporosis International, 1994